Inna Tulaeva1, Carolin Cornelius2, Petra Zieglmayer3, René Zieglmayer3, René Schmutz3, Patrick Lemell3, Milena Weber2, Margarete Focke-Tejkl2, Alexander Karaulov4, Rainer Henning5, Rudolf Valenta6. 1. Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, WähringerGürtel 18-20, 3Q, A-1090 Vienna, Austria; Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 2. Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, WähringerGürtel 18-20, 3Q, A-1090 Vienna, Austria. 3. Vienna Challenge Chamber, Vienna, Austria. 4. Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 5. Viravaxx, Vienna, Austria. 6. Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, WähringerGürtel 18-20, 3Q, A-1090 Vienna, Austria; Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation; NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation; Karl Landsteiner University of Health Sciences, Krems, Austria. Electronic address: rudolf.valenta@meduniwien.ac.at.
Abstract
BACKGROUND:Chronic hepatitis B virus (HBV) infections are a global health problem. There is a need for therapeutic strategies blocking continuous infection of liver cells. The grass pollen allergy vaccine BM32 containing the preS domain of the large HBV surface protein (LHBs) as immunogenic carrier induced IgG antibodies in human subjects inhibiting HBV infection in vitro. Aim of this study was the quantification, epitope mapping and investigation of HBV genotype cross-reactivity of preS-specific antibodies in subjects treated with different dosage regimens of BM32 METHODS:Hundred twenty eight grass pollen allergic patients received in a double-blind, placebo-controlled trial five monthly injections of placebo (aluminum hydroxide, n= 34) or different courses of BM32 (2 placebo + 3 BM32, n= 33; 1 placebo + 4 BM32, n= 30; 5 BM32, n= 31). Recombinant Escherichia coli-expressed preS was purified. Overlapping peptides spanning preS and the receptor-binding sites from consensus sequences of genotypes A-H were synthesized and purified. Isotype (IgM, IgG, IgA, IgE) and IgG subclass (IgG1-IgG4) responses to preS and peptides were determined by ELISA at baseline, one and four months after the last injection. IgG1 and IgG4 subclass concentrations specific for preS and the receptor-binding site were measured by quantitative ELISA. FINDINGS: Five monthly injections induced the highest levels of preS-specific IgG consisting mainly of IgG1 and IgG4, with a sum of median preS-specific IgG1 and IgG4 concentrations of >135 μg/ml reaching up to 1.8 mg/ml. More than 20% of preS-specific IgG was directed against the receptor-binding site. BM32-induced IgG cross-reacted with the receptor-binding domains from all eight HBV genotypes A-H. INTERPRETATION: BM32 induces high levels of IgG1 and IgG4 antibodies against the receptor binding sites of all eight HBV genotypes and hence might be suitable for therapeutic HBV vaccination. FUNDING: This study was supported by the PhD program IAI (KPW01212FW), by Viravaxx AG and by the Danube-ARC funded by the Government of Lower Austria. Rudolf Valenta is a recipient of a Megagrant of the Government of the Russian Federation, grant No 14.W03.31.0024.
RCT Entities:
BACKGROUND:Chronic hepatitis B virus (HBV) infections are a global health problem. There is a need for therapeutic strategies blocking continuous infection of liver cells. The grass pollen allergy vaccine BM32 containing the preS domain of the large HBV surface protein (LHBs) as immunogenic carrier induced IgG antibodies in human subjects inhibiting HBV infection in vitro. Aim of this study was the quantification, epitope mapping and investigation of HBV genotype cross-reactivity of preS-specific antibodies in subjects treated with different dosage regimens of BM32 METHODS: Hundred twenty eight grass pollen allergicpatients received in a double-blind, placebo-controlled trial five monthly injections of placebo (aluminum hydroxide, n= 34) or different courses of BM32 (2 placebo + 3 BM32, n= 33; 1 placebo + 4 BM32, n= 30; 5 BM32, n= 31). Recombinant Escherichia coli-expressed preS was purified. Overlapping peptides spanning preS and the receptor-binding sites from consensus sequences of genotypes A-H were synthesized and purified. Isotype (IgM, IgG, IgA, IgE) and IgG subclass (IgG1-IgG4) responses to preS and peptides were determined by ELISA at baseline, one and four months after the last injection. IgG1 and IgG4 subclass concentrations specific for preS and the receptor-binding site were measured by quantitative ELISA. FINDINGS: Five monthly injections induced the highest levels of preS-specific IgG consisting mainly of IgG1 and IgG4, with a sum of median preS-specific IgG1 and IgG4 concentrations of >135 μg/ml reaching up to 1.8 mg/ml. More than 20% of preS-specific IgG was directed against the receptor-binding site. BM32-induced IgG cross-reacted with the receptor-binding domains from all eight HBV genotypes A-H. INTERPRETATION:BM32 induces high levels of IgG1 and IgG4 antibodies against the receptor binding sites of all eight HBV genotypes and hence might be suitable for therapeutic HBV vaccination. FUNDING: This study was supported by the PhD program IAI (KPW01212FW), by Viravaxx AG and by the Danube-ARC funded by the Government of Lower Austria. Rudolf Valenta is a recipient of a Megagrant of the Government of the Russian Federation, grant No 14.W03.31.0024.
Authors: Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim Journal: Lancet Gastroenterol Hepatol Date: 2019-04-10
Authors: Daniela Gallerano; Portia Ndlovu; Ian Makupe; Margarete Focke-Tejkl; Kerstin Fauland; Eva Wollmann; Elisabeth Puchhammer-Stöckl; Walter Keller; Elopy Sibanda; Rudolf Valenta Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Verena Niederberger; Angela Neubauer; Philippe Gevaert; Mihaela Zidarn; Margitta Worm; Werner Aberer; Hans Jørgen Malling; Oliver Pfaar; Ludger Klimek; Wolfgang Pfützner; Johannes Ring; Ulf Darsow; Natalija Novak; Roy Gerth van Wijk; Julia Eckl-Dorna; Margarete Focke-Tejkl; Milena Weber; Hans-Helge Müller; Joachim Klinger; Frank Stolz; Nora Breit; Rainer Henning; Rudolf Valenta Journal: J Allergy Clin Immunol Date: 2018-01-17 Impact factor: 10.793
Authors: Sasha Babicki; David Arndt; Ana Marcu; Yongjie Liang; Jason R Grant; Adam Maciejewski; David S Wishart Journal: Nucleic Acids Res Date: 2016-05-17 Impact factor: 16.971
Authors: Julia Eckl-Dorna; Milena Weber; Victoria Stanek; Birgit Linhart; Robin Ristl; Eva E Waltl; Sergio Villazala-Merino; Andrea Hummel; Margarete Focke-Tejkl; Renate Froeschel; Angela Neubauer; Rainer Henning; Thomas Perkmann; Rudolf Valenta; Verena Niederberger Journal: EBioMedicine Date: 2019-11-28 Impact factor: 8.143
Authors: Pia Gattinger; Katarzyna Niespodziana; Karin Stiasny; Sabina Sahanic; Inna Tulaeva; Kristina Borochova; Yulia Dorofeeva; Thomas Schlederer; Thomas Sonnweber; Gerhard Hofer; Renata Kiss; Bernhard Kratzer; Doris Trapin; Peter A Tauber; Arno Rottal; Ulrike Körmöczi; Melanie Feichter; Milena Weber; Margarete Focke-Tejkl; Judith Löffler-Ragg; Bernhard Mühl; Anna Kropfmüller; Walter Keller; Frank Stolz; Rainer Henning; Ivan Tancevski; Elisabeth Puchhammer-Stöckl; Winfried F Pickl; Rudolf Valenta Journal: Allergy Date: 2021-09-22 Impact factor: 14.710
Authors: Pia Gattinger; Bernhard Kratzer; Inna Tulaeva; Katarzyna Niespodziana; Anna Ohradanova-Repic; Laura Gebetsberger; Kristina Borochova; Erika Garner-Spitzer; Doris Trapin; Gerhard Hofer; Walter Keller; Isabella Baumgartner; Ivan Tancevski; Musa Khaitov; Alexander Karaulov; Hannes Stockinger; Ursula Wiedermann; Winfried F Pickl; Rudolf Valenta Journal: Allergy Date: 2022-04-15 Impact factor: 14.710
Authors: Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran Journal: Cells Date: 2022-01-08 Impact factor: 6.600